Ardelyx, INC Form 4 insider transactions

ARDELYX, Inc. Director Richard J. Rodgers acquired additional common stock, restricted stock units, and stock options as part of the company's Non-Employee Director Compensation Program.

Ardelyx, Inc. Director Merdad Parsey acquired 15,235 shares of common stock as part of the company's non-employee director compensation program, increasing his total beneficial ownership to 57,291 shares.

ARDELYX Director and 10% Owner David M. Mott has increased his beneficial ownership in the company by acquiring common stock, restricted stock units, and stock options as part of the Non-Employee Director Compensation Program.

ARDELYX, Inc. Director Onaiza Cadoret-Manier has reported the acquisition of 41,551 restricted stock units and 54,059 stock options as part of the company's non-employee director compensation program.

ARDELYX, Inc. Director Muna Bhanji was granted 41,551 Restricted Stock Units (RSUs) and options to purchase 54,059 shares of common stock as part of the company's Non-Employee Director Compensation Program.

Ardelyx, Inc. Director William C. Bertrand Jr. acquired additional common stock, restricted stock units, and stock options as part of the company's Non-Employee Director Compensation Program.

ARDELYX Director and 10% Owner David Mott has significantly increased his beneficial ownership in the company by purchasing 200,000 shares of common stock for approximately $725,880.

ARDELYX Director David Mott acquired 200,000 shares of common stock for approximately $737,260, increasing his beneficial ownership to over 2.69 million shares.

Laura A. Williams, Chief Medical Officer of Ardelvx, Inc., sold 6,421 shares of common stock on May 20, 2025, to cover withholding taxes related to the vesting of restricted stock units.

Justin A. Renz, CFO of Ardelyx, Inc., sold 7,218 shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

Ardelvx CEO Michael Raab sold shares of common stock to cover withholding taxes related to the vesting of restricted stock units.

Mike Kelliher, an officer of Ardelix Inc., sold 14,522 shares of common stock on May 20, 2025, to cover withholding taxes related to the vesting of restricted stock units.

Elizabeth A. Grammer, an officer of Ardelvx, Inc., sold shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

Eric Duane Foster, Chief Commercial Officer of Ardelyx, Inc., sold 2,507 shares of common stock on May 20, 2025, to cover withholding taxes related to the vesting of restricted stock units.

Director David Mott purchased 100,000 shares of Ardelvx, Inc. common stock at an average price of $3.2912 on May 15, 2025.

Director Merdad Parsey reports acquiring shares and stock options in Ardelvx, Inc. on April 28, 2025.

Director David Mott reports purchasing 381,377 shares of Ardelyx, Inc. at an average price of $4.224 on May 2, 2025.

Michael Raab, President and CEO of Ardelvx, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Michael Raab, CEO of Ardelyx, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Ardelix's CEO, Michael Raab, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Laura A. Williams, Chief Medical Officer of Ardelvx, Inc., reports the acquisition of 105,200 shares of common stock and 157,700 stock options.

Chief Financial Officer Justin Renz of Ardelvx, Inc. reports acquiring shares and stock options, as indicated in a recent SEC Form 4 filing.

Ardelvx CEO Michael Raab reports acquisition of shares and stock options, along with disposal of shares held in a family trust.

Mike Kelliher, an executive at Ardelix, Inc., reported the acquisition of common stock and stock options.

Elizabeth Grammer, Chief Legal and Administrative Officer of Ardelix, Inc., reports acquiring shares and stock options in the company.

Chief Commercial Officer Eric Duane Foster reports acquisition of common stock and stock options in Ardelvx, Inc.

Director David Mott reports purchasing 77,729 shares of Ardelyx (ARDX) common stock at an average price of $5.0012 on February 24, 2025.

Laura A. Williams, Chief Medical Officer of Ardelix, Inc., sold shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

Ardelix CFO Justin Renz sold 5,171 shares of common stock on February 20, 2025, to cover withholding taxes related to the vesting of restricted stock units.

Ardelvx CEO Michael Raab sold shares of common stock to cover withholding taxes upon the vesting of restricted stock units.